By Eleanor Laise
Teens and older adults at risk, say doctors and researchers, as Novo Nordisk's Wegovy and Ozempic are hyped heavily online
A national obsession with a new class of weight-loss drugs is turning dangerous, doctors and researchers say, as many patients are inappropriately prescribed Wegovy, Ozempic and similar medications and supply shortages generate a market for unauthorized, potentially risky copycat versions of these drugs.
Social media buzz about the drugs has promoted the mistaken perception that the medications are appropriate for a broad swath of people who may want to shed a few pounds--with disastrous consequences for some patients, doctors say. Patients who previously recovered from eating disorders, for example, are coming in for treatment because they "have had their eating disorder reactivated by use of these medications," said Dr. Elizabeth Wassenaar, a regional medical director at the Eating Recovery Center, which specializes in treating the disorders. Some patients have wound up in the hospital, she said, and in some cases the providers who prescribed the drugs were unaware of the patients' eating-disorder history. "It's a real warning to people who prescribe these medications that it's not without risk," she said.
Some doctors also question whether the safety of the drugs has been adequately studied in older adults, who may have an undesirable loss of lean muscle mass when taking the medications. That complicates an ongoing debate about whether Medicare should cover these drugs for weight loss.
And patients of all types are put at risk, experts say, by the illegal production of knock-off versions of the medications. The Food and Drug Administration and several state pharmacy boards in recent weeks have warned that some compounding pharmacies are producing unauthorized versions of the drugs--which poses particular safety concerns for injectable drugs such as Wegovy, said David Margraf, a pharmaceutical research scientist with the Resilient Drug Supply Project at the University of Minnesota's Center for Infectious Disease Research and Policy. "It's not just a victimless crime," he said. "People can be severely injured."
Novo Nordisk (NOVO-B.KO), the maker of Wegovy and Ozempic, itself sought to tap the brakes on the craze around these drugs in a statement posted on its website this month, saying it's concerned about reports of the drugs being used "for purely cosmetic or aesthetic weight loss," unauthorized versions of the drugs hitting the market, and "insufficient clinical evaluations by some telehealth providers" promoting the drugs.
Drugs such as Novo Nordisk's Wegovy, Ozempic and Rybelsus and Eli Lilly's (LLY) Mounjaro mimic the effects of a gut hormone known as GLP-1, which can help control blood-sugar levels and reduce appetite. (Mounjaro also affects another hormone called GIP.) Ozempic, Rybelsus and Mounjaro are FDA-approved for treatment of type 2 diabetes, while Wegovy is approved for people with obesity and certain people with excess weight combined with weight-related medical problems.
Billions of dollars in drug sales hinge on the breadth of the patient population prescribed these medications. Last year, more than 5 million prescriptions for Ozempic, Mounjaro, Rybelsus or Wegovy were written for weight management, up from just 230,000 in 2019, according to data and analytics firm Komodo Health. Obesity drugs could be a $54 billion market by 2030, up from $2.4 billion in 2022, Morgan Stanley said in a report last year. Reports of GLP-1 drug users seeing improvements in addictive behaviors such as smoking and drinking have lately amplified interest in the medications.
The drugs have become such a cultural phenomenon that Walmart during its quarterly earnings call last week blamed the medications for a shift in consumer-spending patterns that pressured its margins. In the first quarter, the company saw "a shift to health and wellness," John Rainey, Walmart Inc.'s (WMT) executive vice president and chief financial officer, said on the call with analysts. "And part of that is related to these GLP-1 drugs that are to treat diabetes," he said, adding that the shift "comes at a lower margin, and so that has some impact on our business as well."
Noom, a digital health company that for years has emphasized a behavioral approach to weight management, this week announced a new program that will make Ozempic, Wegovy, Mounjaro and other medications available to eligible patients. "Prescriptions are not the goal of our program. They're very much an adjunct," Dr. Linda Anegawa, Noom's chief of medicine, told MarketWatch. Medical professionals will review patients' entire health history, order labs to assess their metabolic health, and engage in video visits with patients as they determine what treatments might be appropriate, she said.
Telling your brain you're not hungry
The reason GLP-1 drugs help control weight is pretty straightforward, said Dr. Daniel Drucker, who helped discover GLP-1 and is senior scientist at Lunenfeld-Tanenbaum Research Institute in Toronto. When people take these drugs, he said, they simply eat less because they feel more full. "GLP-1 will tell your brain that you're not hungry," he said, and people taking these medications may feel less stressed about food or find themselves thinking less about food. And the effects may go beyond eating, he said, as some people also see improvements in smoking, drinking, and other addictive or compulsive behaviors. "These are really interesting areas for further investigation," he said. Drucker has been a consultant or speaker for Novo Nordisk, Pfizer (PFE) and other pharmaceutical companies.
Novo Nordisk said in a statement to MarketWatch that it is not conducting any dedicated clinical studies to evaluate Ozempic, Rybelsus or Wegovy in patients with substance-use disorders or addiction-related illnesses, and Eli Lilly said it does not have any studies planned for investigating tirzepatide--the active ingredient in Mounjaro--for treatment of addiction.
Adolescents' use of the drugs for weight loss is a particular concern for some doctors. Wegovy is approved for treatment of obesity in children 12 and older. "The adolescent mental health crisis is unprecedented," said Wassenaar, with many teens suffering severe mood disorders, eating disorders, and suicidality, and teens struggling with depression may think, "if I lose weight, I'll feel better and people will like me. There's this magic drug, and all I have to do is inject it." And if patients can start taking these drugs as early as 12 years of age, "we just don't know what that's going to do to them in 10 or 20 years," she said, because there's not enough long-term data.
Novo Nordisk said in a statement to MarketWatch that "teenage obesity is linked to weight-related health problems such as high blood pressure, high cholesterol and type 2 diabetes," and that cutting calories and increasing physical activity may not be enough for some patients. "The decision to prescribe an anti-obesity medication is at the discretion of the physician and the patient/parents," the company said.
Eli Lilly said that tirzepatide is not currently being studied for chronic weight management in children or adolescents.
Some doctors are also concerned about broad use of the drugs among older adults. Many older adults have sarcopenia, an age-related loss of muscle mass and strength that can contribute to frailty and fall risk later in life--and losing weight can mean an additional loss of muscle mass that may not be advisable for some patients, doctors and researchers say.
While "there's a huge push to get Medicare to cover these drugs, it's not really certain whether they would be helpful in this population or actually more harmful," said Judy Butler, a research fellow at PharmedOut, a research and education project at Georgetown University Medical Center. Noom is not enrolling patients over age 60 in its new program, Anegawa said, partly because "we really don't have enough data yet with many of these drugs in the geriatric population."
In the pivotal clinical trials for Wegovy, 9% of the Wegovy-treated patients were between 65 and 75 years of age, and 1% were 75 and older, Novo Nordisk said in a statement. "No overall differences in safety or effectiveness have been observed between patients 65 years of age and older and younger adult patients," the company said. In an ongoing cardiovascular outcomes trial, about 38% of patients are 65 or older, the company said.
By law, Medicare generally does not cover drugs prescribed for weight loss--although some drugmakers and industry groups are pushing to change that. Some of the drugs now generating intense demand also come with a hefty sticker price: Wegovy, for example, has an estimated annual net cost of about $13,600, according to the Institute for Clinical and Economic Review. If Medicare coverage rules changed and 10% of beneficiaries with obesity used Wegovy, total annual Medicare Part D spending on the drug could be as much as $26.8 billion, according to a recent study published in the New England Journal of Medicine. That's more than 18% of the net total Part D spending by beneficiaries and the Medicare program in 2019.
Dangerous copycats
There are potential physical as well as financial costs. Side effects of the drugs can range from nausea and vomiting to gallbladder problems, inflammation of the pancreas, and thyroid cancer.
More broadly, some doctors question the prescribing of drugs solely based on obesity, absent other risk factors. "If somebody is obese and has diabetes, high blood pressure, and high cholesterol, losing weight may improve those parameters, but obesity on its own does not need to be treated," said Dr. Adriane Fugh-Berman, a professor at Georgetown University Medical Center and director of PharmedOut. "It's cardiovascular fitness that is important, no matter what weight you are," she said. "We should stop focusing on the weight itself as a risk factor."
(MORE TO FOLLOW) Dow Jones Newswires
05-27-23 1108ET
Copyright (c) 2023 Dow Jones & Company, Inc.The dark side of the weight-loss-drug craze: eating disorders, medication shortages, dangerous knockoffs - Morningstar
Read More
No comments:
Post a Comment